Remote tDCS + Somatosensory Training for Phantom Limb Pain
(PLP-EVEREST Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new home-based treatment for phantom limb pain (PLP), which is pain felt in an amputated limb. Researchers compare two approaches: one group uses a portable device for brain stimulation (M1 anodal home-based tDCS, a type of transcranial direct current stimulation) with somatosensory training, while the other group continues with usual care, such as medication and physical therapy. The goal is to determine if the new combined treatment reduces pain more effectively. Individuals who have had a limb amputation and experience PLP at least once a week may be suitable for this trial. As an unphased trial, this study provides a unique opportunity to explore innovative treatments for PLP in a flexible research setting.
Will I have to stop taking my current medications?
No, you will not have to stop taking your current medications. The trial allows participants to continue their usual care, including current medications, physical therapy, and occupational therapy.
What prior data suggests that this device is safe for home-based use?
Research has shown that using transcranial direct current stimulation (tDCS) at home is generally safe for people with phantom limb pain. Previous studies used this treatment without causing harmful effects. It works by sending a small, gentle electrical current through the scalp to the brain, and patients usually tolerate it well.
Studies have also found that somatosensory training, which includes exercises involving the senses, can safely help reduce phantom limb pain. Participants in these studies did not report any major negative effects.
Both treatments in this trial have been tested in similar situations without serious safety issues. This suggests they are likely safe, but discussing any concerns with the trial team or a healthcare professional is always important.12345Why are researchers excited about this trial?
Researchers are excited about using M1 anodal home-based transcranial direct current stimulation (tDCS) combined with somatosensory training for phantom limb pain because it offers a non-invasive, at-home approach to pain management. Unlike traditional treatments that often rely on medications, physical therapy, or behavioral therapy, this method uses low-level electrical currents applied directly to the scalp, which can modulate brain activity to alleviate pain. This innovative approach not only provides a new mechanism of action by directly targeting brain activity but also empowers patients to manage their treatment conveniently at home, potentially enhancing adherence and outcomes.
What evidence suggests that this trial's treatments could be effective for phantom limb pain?
Research has shown that transcranial direct current stimulation (tDCS) can provide lasting relief from phantom limb pain (PLP). One study found that individuals who had lost a limb experienced significant pain relief after receiving tDCS on the brain's motor area for five days. Additionally, somatosensory training reduced PLP by 32.1% six weeks after the training, with participants reporting less pain by the end of each training day. In this trial, one group of participants will receive M1 anodal home-based tDCS combined with somatosensory training, which may effectively reduce PLP. Another group will continue with their usual care, including pharmacological treatments, physical therapy, occupational therapy, and/or behavioral therapy.12346
Are You a Good Fit for This Trial?
This trial is for adults over 18 with limb amputations who regularly experience phantom limb pain (PLP) at least once a week, and have chronic pain rated at least 4 on the numeric rating scale. It's not suitable for those with significant medical or psychiatric disorders, recent substance abuse, uncompensated psychiatric conditions, major neurological history or neurosurgery affecting tDCS distribution, or implanted brain devices.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 20 daily sessions of active anodal M1 home-based tDCS combined with somatosensory training or usual care
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- M1 anodal home-based tDCS
- Somatosensory Training
M1 anodal home-based tDCS is already approved in United States, European Union for the following indications:
- Phantom Limb Pain
- Phantom Limb Pain
- Neuropathic Pain
Find a Clinic Near You
Who Is Running the Clinical Trial?
Spaulding Rehabilitation Hospital
Lead Sponsor